Tango Therapeutics, Inc. (TNGX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Tango Therapeutics, Inc.
Address
201 Brookline Avenue
Boston, MA 02142
United States of America (the)
Phone
857 320 4900
Website
Sector
Healthcare
Industry
Biotechnology
Employees
137
First IPO Date
September 03, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Malte Peters | President, Chief Executive Officer & Director | 148,315 | 1962 |
| Matthew Gall | Chief Financial Officer | 717,616 | 1977 |
| Daniella Beckman | Executive Officer | 765,152 | 1979 |
| Adam S. Crystal | President of Research & Development | 928,209 | 1977 |
| Barbara L. Weber | Founder & Executive Chairman of the Board | 1.24M | 1957 |
| Philippe Serrano | Chief Regulatory Officer | 0 | N/A |
| Antoni Ribas | Founder & Member of Scientific Advisory Board | 0 | 1967 |
| William G. Kaelin Jr. | Founder & Member of Scientific Advisory Board | 0 | 1958 |
| Alan Ashworth | Founder & Member of Scientific Advisory Board | 0 | 1961 |
| Julie Fogarty | Vice President of Legal & Corporate Secretary | 0 | N/A |
| Jannik N. Andersen | Chief Scientific Officer | 0 | N/A |
| Elizabeth Pingpank Hickin | Vice President of IR & Corporate Communications | 0 | N/A |
Description
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
